找回密码
 To register

QQ登录

只需一步,快速开始

扫一扫,访问微社区

Titlebook: Innovative Antimetabolites in Solid Tumours; Matti S. Aapro Conference proceedings 1994 Springer-Verlag Berlin Heidelberg 1994 Antimetabol

[复制链接]
查看: 55556|回复: 42
发表于 2025-3-21 17:14:38 | 显示全部楼层 |阅读模式
书目名称Innovative Antimetabolites in Solid Tumours
编辑Matti S. Aapro
视频video
丛书名称ESO Monographs
图书封面Titlebook: Innovative Antimetabolites in Solid Tumours;  Matti S. Aapro Conference proceedings 1994 Springer-Verlag Berlin Heidelberg 1994 Antimetabol
描述The European School of Oncology came into existence to respond to a need for information, education and training in the field of the diagnosis and treatment of cancer. There are two main reasons why such an initiative was considered necessary. Firstly, the teaching of oncology requires a rigorously multidisciplinary approach which is difficult for the Universities to put into practice since their system is mainly disciplinary orientated. Secondly, the rate of technological development that impinges on the diagnosis and treatment of cancer has been so rapid that it is not an easy task for medical faculties to adapt their curricula flexibly. With its residential courses for organ pathologies and the seminars on new techniques (laser, monoclonal antibodies, imaging techniques etc.) or on the principal therapeutic controversies (conservative or mutilating surgery, primary or adjuvant chemotherapy, radiotherapy alone or integrated), it is the ambition of the European School of Oncology to fill a cultural and scientific gap and, thereby, create a bridge between the University and Industry and between these two and daily medical practice. One of the more recent initiatives of ESO has been
出版日期Conference proceedings 1994
关键词Antimetabolit; Antimetabolite; Antimetabolites; Cladribin; Onkologie; breast cancer; cancer; cancer treatme
版次1
doihttps://doi.org/10.1007/978-3-642-79200-7
isbn_softcover978-3-642-79202-1
isbn_ebook978-3-642-79200-7
copyrightSpringer-Verlag Berlin Heidelberg 1994
The information of publication is updating

书目名称Innovative Antimetabolites in Solid Tumours影响因子(影响力)




书目名称Innovative Antimetabolites in Solid Tumours影响因子(影响力)学科排名




书目名称Innovative Antimetabolites in Solid Tumours网络公开度




书目名称Innovative Antimetabolites in Solid Tumours网络公开度学科排名




书目名称Innovative Antimetabolites in Solid Tumours被引频次




书目名称Innovative Antimetabolites in Solid Tumours被引频次学科排名




书目名称Innovative Antimetabolites in Solid Tumours年度引用




书目名称Innovative Antimetabolites in Solid Tumours年度引用学科排名




书目名称Innovative Antimetabolites in Solid Tumours读者反馈




书目名称Innovative Antimetabolites in Solid Tumours读者反馈学科排名




单选投票, 共有 1 人参与投票
 

0票 0.00%

Perfect with Aesthetics

 

0票 0.00%

Better Implies Difficulty

 

0票 0.00%

Good and Satisfactory

 

1票 100.00%

Adverse Performance

 

0票 0.00%

Disdainful Garbage

您所在的用户组没有投票权限
发表于 2025-3-21 20:20:28 | 显示全部楼层
发表于 2025-3-22 02:32:30 | 显示全部楼层
Thymidylate Synthase Inhibitors, Modulation of 5-Fluorouracil and Folate Analogues,to clinical practice. The effects of 5-fluorouracil on the cell are 1) inhibition of thymidylate synthase, 2) a direct effect on DNA, and 3) a direct effect on RNA [1]. These mechanisms and their modulation by other factors designed to increase activation, response rates and survival, will be discus
发表于 2025-3-22 07:58:55 | 显示全部楼层
A Review of Fludarabine and Cladribine in Solid Tumours,ancies such as hairy cell leukaemia, low-grade non-Hodgkin’s lymphoma, chronic lymphocytic leukaemia, Waldenström macroglobulinaemia and cutaneous T-cell lymphoma [1,2]. Both have also been used in acute leukaemias and fludarabine appears particularly promising for this indication [3]. Activation of
发表于 2025-3-22 10:04:57 | 显示全部楼层
Gemcitabine in Ovarian Cancer,dard practice. It is obvious that new drugs are needed to improve the results in advanced disease. Recently the introduction of taxanes in the treatment of ovarian cancer has engendered hope that treatment may further improve. Gemcitabine is another promising candidate to be added to the list of dru
发表于 2025-3-22 14:48:25 | 显示全部楼层
Gemcitabine Therapy in Non-Small Cell Lung Cancer: A Review,last decade. Few single agents have, in large studies, achieved response rates of more than 15%, while combination treatment gives response rates of 25% to 35% [1–4]. Several randomised studies comparing chemotherapy with best supportive care have yielded predominantly slightly favourable results fo
发表于 2025-3-22 17:39:17 | 显示全部楼层
发表于 2025-3-23 00:14:52 | 显示全部楼层
发表于 2025-3-23 03:06:29 | 显示全部楼层
发表于 2025-3-23 09:15:25 | 显示全部楼层
A Review of Fludarabine and Cladribine in Solid Tumours,nce between activation and degradation appears crucial for their clinical activity [4]. FAMP and CDA are cytotoxic not by inducing necrosis but rather programmed cell death, apoptosis, by means of activation of specific endonucleases [5].
 关于派博传思  派博传思旗下网站  友情链接
派博传思介绍 公司地理位置 论文服务流程 影响因子官网 SITEMAP 大讲堂 北京大学 Oxford Uni. Harvard Uni.
发展历史沿革 期刊点评 投稿经验总结 SCIENCEGARD IMPACTFACTOR 派博系数 清华大学 Yale Uni. Stanford Uni.
|Archiver|手机版|小黑屋| 派博传思国际 ( 京公网安备110108008328) GMT+8, 2025-5-24 16:22
Copyright © 2001-2015 派博传思   京公网安备110108008328 版权所有 All rights reserved
快速回复 返回顶部 返回列表